Analyst Ratings For CareDx Inc (NASDAQ:CDNA)
Today, HC Wainwright reiterated its Neutral rating on CareDx Inc (NASDAQ:CDNA) with a price target of $22.00.
There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on CareDx Inc (NASDAQ:CDNA) is Buy with a consensus target price of $20.1250 per share, a potential 22.72% downside.
Some recent analyst ratings include
- 9/18/2018-CareDx Inc (NASDAQ:CDNA) had its Neutral rating reiterated by HC Wainwright with a $22.00 price target
- 10/9/2017-CareDx Inc (NASDAQ:CDNA) had its Buy rating reiterated by Craig Hallum with a $10.00 price target
- 9/27/2017-CareDx Inc (NASDAQ:CDNA) gets upgraded to Buy by Raymond James with a price target of $6.50
Recent Insider Trading Activity For CareDx Inc (NASDAQ:CDNA)
CareDx Inc (NASDAQ:CDNA) has insider ownership of 3.40% and institutional ownership of 72.84%.
- On 9/13/2018 Michael Brian Bell, CFO, sold 16,355 with an average share price of $25.06 per share and the total transaction amounting to $409,856.30.
- On 9/4/2018 Peter Maag, Insider, sold 15,000 with an average share price of $23.10 per share and the total transaction amounting to $346,500.00.
- On 8/14/2018 Michael Brian Bell, CFO, sold 12,500 with an average share price of $16.84 per share and the total transaction amounting to $210,500.00.
- On 8/1/2018 Sasha King, Insider, sold 9,458 with an average share price of $14.03 per share and the total transaction amounting to $132,695.74.
- On 7/2/2018 Mitchell J Nelles, COO, sold 39,649 with an average share price of $12.48 per share and the total transaction amounting to $494,819.52.
- On 4/26/2018 Neil Gagnon, Major Shareholder, bought 10,136 with an average share price of $9.42 per share and the total transaction amounting to $95,481.12.
- On 3/27/2018 Peter Maag, Insider, sold 15,000 with an average share price of $7.87 per share and the total transaction amounting to $118,050.00.
About CareDx Inc (NASDAQ:CDNA)
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics. The Post-Transplant Diagnostics segment develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell free DNA test initially used for kidney transplant patients. The Pre-Transplant Diagnostics segment develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HAL) alleles based on sequence-specific primer technology; Olerup QTYPE, a test kit for sequence based HLA typing; Olerup SBT, a test kit for sequence based HLA typing; and XM-ONE, a test that identifies a patient's antigens against HLA Class I or Class II, as well as antibodies against a donor's endothelium. This segment offers its products directly to customers, as well as through third-party distributors. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
Recent Trading Activity for CareDx Inc (NASDAQ:CDNA)
Shares of CareDx Inc closed the previous trading session at 26,04 −0,12 0,46 % with 589800 shares trading hands.